New clinical data reveals ExSpiron™ patient monitoring surpasses other measures in recognizing early signs of life-threatening and costly respiratory depression
Waltham, MA (PRWEB) March 01, 2016 -- Respiratory Motion, Inc. developer of the ExSpiron, the only patient monitor measuring non-invasive Minute Ventilation, announces clinical study results showing the effectiveness of Minute Ventilation monitoring in early identification of respiratory depression episodes.
The study used the ExSpiron respiratory volume monitor to assess the clinical utility of non-invasive Minute Ventilation monitoring versus only respiratory rate monitoring and was conducted at the Massachusetts General Hospital. Results from the study were presented at the Society of Critical Care Medicine congress by Dr. Edward George, MD, PhD, Medical Director of Post Operative Care Units and Assistant Professor Anaesthesia at Harvard Medical School.
In his presentation, Dr. George described the utility of the ExSpiron to evaluate respiratory depression in 204 patients following orthopedic surgery, with specific analysis of 11,686 paired minute ventilation (MV) and respiratory rate (RR) measurements collected during the 30 min prior to discharge from the post-anesthesia care unit (PACU).
Study results demonstrate that a low RR alarm (set at 6 breaths / min) would miss 84.3% of respiratory depression episodes revealed by a Low MV measurement (set at 40% of normal). The study found that low RR alone does not accurately reflect inadequate patient ventilation and is insufficient for assessing respiratory status.
In addition, the investigators found that patients that developed Low MV while in the PACU had longer PACU stays vs patients with Adequate MV throughout (2.8 vs 2.4 hrs, p<0.001). In particular, patients on opioids had an increased likelihood of respiratory depression (Low MV) and patients receiving opioids who developed Low MV incurred a 75% longer PACU stay than patients receiving opioids without Low MV (3.0 vs 1.7, p<0.001).
The investigators concluded that “in many patients, Low MV is primarily related to a decrease in tidal volume and not respiratory rate. Respiratory Volume Monitoring provides non-invasive, real-time measurements, which can better assess the adequacy of ventilation when considering discharge or transfer to a lower-acuity setting, preventing prolonged PACU or ICU stays, reducing extra healthcare costs, and reducing life-threatening respiratory complications.”
About SCCM:
Society of Critical Care Medicine, is the leading organization dedicated to ensuring excellence and consistency in the practice of critical care. From heart attack and stroke, to severe respiratory insufficiency, overwhelming infection, burns and gunshot wounds, the SCCM recognizes the unique needs of the critically ill patient of any age -- infant to adult -- and strives to secure the highest quality care for all patients facing life-threatening conditions.
Critical care evolved from a historical recognition that patients with acute, life-threatening illness or injury could be better treated if they were grouped into specific areas of the hospital.
To learn more, visit http://www.sccm.org
About Respiratory Motion, Inc.
Respiratory Motion, Inc. is a medical device company based in Waltham, MA, that develops innovative technology to monitor respiration and help clinicians and hospitals improve patient safety and outcomes. The company’s monitoring systems can identify patients who are at risk for life-threatening respiratory depression. This allows physicians to prevent the dangerous condition before it harms a patient. To learn more, visit http://www.respiratorymotion.com
Jack Auer, Respiratory Motion, Inc., http://www.respiratorymotion.com, +1 (781)354-8051, [email protected]
Share this article